Great Ormond Street Hospital

The world’s oldest conjoined twins have died – what we know about this rare condition

Retrieved on: 
Friday, April 19, 2024

The world’s oldest conjoined twins, Lori and George Schappell, recently died, aged 62.

Key Points: 
  • The world’s oldest conjoined twins, Lori and George Schappell, recently died, aged 62.
  • Conjoined twins are incredibly rare, accounting for about one or two in every 100,000 births.
  • Because conjoined twins are so rare, it is difficult to know exactly how they come about.

Types of conjoined twins

  • There are 15 recognised types of conjoined twins, based on the various places their bodies fuse.
  • Conjoined twins are usually picked up on routine ultrasound scans performed during pregnancy.
  • Conjoined twins who are diagnosed by imaging are typically delivered by caesarean section.

Separating twins

  • One of the longest operations to separate conjoined twins, who were fused at the cranium, took more than 100 hours.
  • The earliest recorded attempt at surgical separation of conjoined twins dates back to AD945 in Armenia where conjoined brothers lived until middle age before one of them died.
  • Separating conjoined twins requires a significant amount of planning before surgery can begin, including, of course, lots of imaging such as ultrasound, CT and MRI.
  • Twins who share vital organs – or whose organs are fused – have a lower chance of a successful separation.


Adam Taylor does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Zura Bio Continues to Strengthen Leadership with Appointment of Robert Lisicki as President and Kiran Nistala as CMO

Retrieved on: 
Monday, January 8, 2024

Mr. Lisicki will be responsible for developing and driving the business plan and strategic initiatives as Zura Bio builds a leading immunology company.

Key Points: 
  • Mr. Lisicki will be responsible for developing and driving the business plan and strategic initiatives as Zura Bio builds a leading immunology company.
  • Mr. Lisicki and Dr. Nistala have successfully worked on or led in the development of multiple drugs within the auto-immune therapeutic area.
  • These executives position Zura Bio to deliver on the promise of their innovative medicines for patients in need of better clinical outcomes.
  • View the full release here: https://www.businesswire.com/news/home/20240108851979/en/
    “I am very pleased to welcome Rob and Kiran to Zura Bio as members of the Executive Team.

Code Ninjas Elevates National Hack-A-Thon to New Heights in 2023

Retrieved on: 
Friday, December 8, 2023

PEARLAND, Texas, Dec. 8, 2023 /PRNewswire/ -- Code Ninjas, a renowned name in children's coding education, announced today the winners of its nationwide Hack-A-Thon, a charitable initiative to raise awareness and generate interest in computer science education.

Key Points: 
  • DrLupo's involvement as a celebrity judge added a special flair to the event, combining the excitement of gaming and streaming with educational initiatives in coding.
  • This year's Hack-A-Thon, held from October 10 to November 1 at participating Code Ninjas centers, combined coding challenges with charitable efforts, emphasizing computer science education and community support.
  • "I am thrilled and deeply grateful that Code Ninjas chose to support Children's Miracle Network Hospitals through Extra Life," said Jeff Montegut, Director of Programs for Extra Life.
  • Code Ninjas teaches coding to children ages 7-14 through a fun and interactive curriculum inspired by martial arts.

ViroCell and Great Ormond Street Hospital Poised to Unlock Clinical Trial ‘Backlog’ Following MHRA Manufacturing Approval

Retrieved on: 
Wednesday, November 1, 2023

This shortage in clinical trial vector supply is believed to be slowing the progress of bringing novel medicines to patients.

Key Points: 
  • This shortage in clinical trial vector supply is believed to be slowing the progress of bringing novel medicines to patients.
  • With ViroCell now able to leverage GOSH's state-of-the-art manufacturing facility, the Company is poised to relieve the strain on clinical research caused by the vector shortage and expand the supply of precisely engineered viral vectors for clinical trials.
  • The MHRA is widely considered a gold-standard regulatory authority, with its rigorous requirement for facility inspection and licencing for advanced therapy manufacturing for clinical trials.
  • Therefore, in addition to accelerating CGT clinical trials in the UK, this approval could also help accelerate the start of new clinical trials worldwide, as ViroCell ramps up the manufacturing of vectors for global export.

Parker Moss to Join Exscientia as EVP, Corporate Development

Retrieved on: 
Tuesday, October 17, 2023

Exscientia plc (Nasdaq: EXAI) today announced the appointment of Parker Moss as Executive Vice President, Corporate Development, effective January, 2024.

Key Points: 
  • Exscientia plc (Nasdaq: EXAI) today announced the appointment of Parker Moss as Executive Vice President, Corporate Development, effective January, 2024.
  • In this newly established role, Parker will lead the creation and execution of a focused corporate development strategy to strengthen further and create new market opportunities for the company’s precision medicine, clinical and tech innovation platforms, with a particular focus on oncology.
  • Parker is also the co-lead of Genomics England’s research programme in cancer and rare disease.
  • Parker also holds several non-executive roles, including on the Cancer Research Horizons board (a company wholly owned by Cancer Research UK).

ViroCell Appoints Brian Collins as CFO

Retrieved on: 
Wednesday, July 26, 2023

ViroCell Biologics (“ViroCell” or the “Company”), a specialist Contract Development and Manufacturing Organisation (“CDMO”) in cell and gene therapy clinical trials, announces the appointment of Brian Collins as Chief Financial Officer (“CFO”).

Key Points: 
  • ViroCell Biologics (“ViroCell” or the “Company”), a specialist Contract Development and Manufacturing Organisation (“CDMO”) in cell and gene therapy clinical trials, announces the appointment of Brian Collins as Chief Financial Officer (“CFO”).
  • John W. Hadden II, CEO at ViroCell, commented, “I am delighted to welcome Brian to the ViroCell team.
  • Prior to the CGT Catapult, Brian was the CFO of Coveris Packaging and before that held numerous financial and operational roles of increasing seniority at companies, including MSX International, HB Fuller and Avery Dennison.
  • Throughout his 30-year career in finance, Brian has built finance operations, led acquisitions, and secured company financings.

Emergex Appoints Sir Michael Rake as Board Chairman

Retrieved on: 
Thursday, June 29, 2023

ABINGDON, United Kingdom, June 29, 2023 (GLOBE NEWSWIRE) -- Emergex Vaccines Holding Limited (‘Emergex’), a clinical-stage biotechnology company addressing major global infectious diseases through the development of fully synthetic T cell-priming immune set-point candidates, today announced the appointment of Sir Michael Rake as Chairman of the Board.

Key Points: 
  • ABINGDON, United Kingdom, June 29, 2023 (GLOBE NEWSWIRE) -- Emergex Vaccines Holding Limited (‘Emergex’), a clinical-stage biotechnology company addressing major global infectious diseases through the development of fully synthetic T cell-priming immune set-point candidates, today announced the appointment of Sir Michael Rake as Chairman of the Board.
  • Sir Michael takes on this role from Finian Tan, Ph.D., who becomes Emergex’s Deputy Chairman.
  • Sir Michael has had a long and distinguished career in international business as a Senior Executive and Board leader over several decades.
  • Sir Michael Rake, the new Chairman at Emergex, commented: “I look forward to joining the Emergex Board as Chairman and sharing my experience and network to help grow the business at such a pivotal time in the company’s evolution.

ISHLT 2023 Annual Meeting Awards Showcase Advances in Treatment of Advanced Heart and Lung Disease

Retrieved on: 
Friday, June 2, 2023

Chicago, IL, June 02, 2023 (GLOBE NEWSWIRE) -- The International Society for Heart and Lung Transplantation 43rd Annual Meeting & Scientific Sessions included more than 1,250 presentations on improving outcomes for patients with advanced heart and lung disease from investigators from around the world.

Key Points: 
  • Chicago, IL, June 02, 2023 (GLOBE NEWSWIRE) -- The International Society for Heart and Lung Transplantation 43rd Annual Meeting & Scientific Sessions included more than 1,250 presentations on improving outcomes for patients with advanced heart and lung disease from investigators from around the world.
  • All conference abstracts are available in a special supplement to the Journal of Heart and Lung Transplantation’s April 2023 issue.
  • The team evaluated donor characteristics associated with heart acceptance in the USA and applied modern analytic methods to improve the prediction of heart acceptance.
  • Purpose: Heart transplant remains the gold standard treatment for patients with advanced heart failure.

Eloxx Pharmaceuticals Intends to Advance ELX-02 into Pivotal Trial for the Treatment of Alport Syndrome with Nonsense Mutations Following Achievement of Remission in Patient in Phase 2 Study

Retrieved on: 
Wednesday, May 24, 2023

WATERTOWN, Mass., May 24, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that the company intends to advance ELX-02 into a pivotal trial for the treatment of Alport syndrome with nonsense mutations, following the achievement of remission in one patient in its Phase 2 clinical study. The patient demonstrated a significant reduction in urine protein creatinine ratio (UPCR) from baseline. Consistent with prior clinical studies, ELX-02 was well tolerated in this trial.

Key Points: 
  • Consistent with prior clinical studies, ELX-02 was well tolerated in this trial.
  • One patient that has completed dosing achieved a remission, defined as a UPCR decline greater than or equal to 50%.
  • The patient achieving remission also demonstrated a significant reduction (-49%) (-p-value p=0.009) in UPCR from baseline versus values collected over the treatment period.
  • “We are incredibly pleased with these initial findings from our Phase 2 trial of ELX-02 for the treatment of Alport syndrome in patients with nonsense mutations.

3M Health Information Systems collaborates with AWS to accelerate AI innovation in clinical documentation

Retrieved on: 
Tuesday, April 18, 2023

Minn., April 18, 2023 /PRNewswire/ -- 3M Health Information Systems (HIS) announces a collaboration with Amazon Web Services (AWS) to accelerate the innovation and advancement of 3M M*Modal ambient intelligence.

Key Points: 
  • Minn., April 18, 2023 /PRNewswire/ -- 3M Health Information Systems (HIS) announces a collaboration with Amazon Web Services (AWS) to accelerate the innovation and advancement of 3M M*Modal ambient intelligence.
  • Working with AWS, 3M HIS will advance its conversational AI platform, which is currently preferred by more than 300,000 clinicians.
  • This collaboration expands on 3M HIS' early success in bringing conversational AI and ambient intelligence directly into clinical documentation workflows through 3M Fluency Align.
  • "The innovation, security and reliability of AWS helps us accelerate the delivery of high-quality clinical documentation.